MDM2-p53轴代表了瘤干细胞独特的治疗脆弱性
Yurika Nakagawa-Saito1, Yuta Mitobe1,2, Keita Togashi1,3
1Department of Molecular Cancer Science, School of Medicine, Yamagata University, 2-2-2 Iida-Nishi, Yamagata 990-9585, Japan.
International journal of molecular sciences
|April 13, 2024
概括
向质母细胞干细胞中的MDM2提供了一个新的治疗策略. 抑制MDM2激活p53通路,导致癌细胞死亡,并可能改善患者的生存率.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症干细胞研究研究
背景情况:
- 质母细胞瘤的复发与耐治疗性质母细胞有关.
- 识别质瘤干细胞中的独特漏洞对于有效治疗至关重要.
- MDM2 (鼠标双分钟2同类) 是p53的一个关键调节器.
研究的目的:
- 研究质瘤干细胞与非干细胞中的MDM2表达.
- 评估MDM2抑制在质母细胞瘤中的治疗潜力.
- 阐明MDM2抑制作用背后的分子机制.
主要方法:
- 在不同质瘤细胞种群中对MDM2表达的定量分析.
- 基因和药理上的抑制MDM2.
- 评估细胞活力和细胞亡.
- 对下游分子通路的分析,包括p53,BAX,PUMA和生存.
主要成果:
- 与非干细胞相比,质瘤干细胞中的MDM2表达显著更高.
- 抑制MDM2 (遗传或药理) 诱导了更大的p53激活和质瘤干细胞的亡.
- 抑制MDM2导致BAX和PUMA增加,生存率降低,促进质瘤干细胞亡.
- 非干细胞质母细胞对MDM2抑制剂的敏感性较低.
结论:
- MDM2-p53轴在质瘤干细胞中代表了一个独特的治疗漏洞.
- 向MDM2可能通过选择性消除干细胞为质母细胞瘤治疗提供一种新的策略.
- 这些发现可能有助于选择可能受益于MDM2抑制剂治疗的质母细胞瘤患者.
更多相关视频
相关概念视频
Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
DNA Damage can Stall the Cell Cycle
9.1K
In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
9.1K
Cancer Stem Cells and Tumor Maintenance
4.9K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
4.9K
Drugs that Stabilize Microtubules
2.0K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K


